CIRCULOGENE is a leading provider of comprehensive blood-based liquid biopsy tests, offering the most advanced DNA and RNA detection for clinically significant tumor alterations. With a patented methodology that increases DNA yield and preserves fragile RNA, CIRCULOGENE utilizes next-generation sequencing and polymerase chain reaction instrumentation to provide a wide range of menu offerings, including TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels. Their innovative approach aids oncologists in personalizing and monitoring treatment plans, resulting in better outcomes and survival for cancer patients.
By combining NGS and PCR technologies, CIRCULOGENE ensures accurate results and a comprehensive marker portfolio. Their liquid biopsy method includes plasma PD-L1, providing valuable information for immunotherapy patients. Additionally, CIRCULOGENE's MSI protocol offers greater sensitivity for MSI detection in cancers where results may be inconclusive. With personalized patient reports and referenced information on FDA-approved treatment options, CIRCULOGENE is dedicated to providing the best possible treatment for every patient.
Generated from the website